APRIL/TNFSF13, an immune checkpoint molecule, is overexpressed in colorectal and glioma tissues and has been linked to adverse pathological features and poor prognosis, suggesting its potential as a therapeutic target (83, 84). Here, TNFSF13 is linked to central nervous system cancer.